The potential of cancer immunotherapy is hampered by the poor immunogenicity of cancer cells. Strategies to enhance tumor immunogenicity are imperative to enhance T cell-mediated anti-tumor immunity. Although conventional therapeutics can increase tumor antigen expression or stimulate the release of danger signals to promote immunogenic cell death (ICD), they face challenges relating to efficacy and tumor-specific delivery. Nanomedicines can efficiently deliver tumor antigens, immune adjuvants, epigenetic modulators, or ICD inducers through targeted drug delivery with minimal off-target effects. Collectively, nanomedicines can overcome biological barriers to immunotherapy through targeted antigen delivery, induction of ICD, or epigenetic remodeling, resulting in increased tumor immunogenicity.

中文翻译：

---

纳米药物作为肿瘤免疫原性增强剂以增强癌症免疫治疗

癌细胞免疫原性差阻碍了癌症免疫疗法的潜力。增强肿瘤免疫原性的策略对于增强 T 细胞介导的抗肿瘤免疫至关重要。尽管传统疗法可以增加肿瘤抗原表达或刺激危险信号的释放以促进免疫原性细胞死亡（ICD），但它们面临着功效和肿瘤特异性递送相关的挑战。纳米药物可以通过靶向药物递送有效地递送肿瘤抗原、免疫佐剂、表观遗传调节剂或ICD诱导剂，并且脱靶效应最小。总的来说，纳米药物可以通过靶向抗原递送、ICD诱导或表观遗传重塑来克服免疫治疗的生物障碍，从而增强肿瘤免疫原性。